JP2012502927A - Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体 - Google Patents

Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体 Download PDF

Info

Publication number
JP2012502927A
JP2012502927A JP2011527166A JP2011527166A JP2012502927A JP 2012502927 A JP2012502927 A JP 2012502927A JP 2011527166 A JP2011527166 A JP 2011527166A JP 2011527166 A JP2011527166 A JP 2011527166A JP 2012502927 A JP2012502927 A JP 2012502927A
Authority
JP
Japan
Prior art keywords
amino
acetic acid
methyl
indol
tetrahydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011527166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502927A5 (enExample
Inventor
コルツチ，ジヨン
ボイド，マイケル
ザハダン，モハメド・ヘルミ
ギヤラン，ミツシエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of JP2012502927A publication Critical patent/JP2012502927A/ja
Publication of JP2012502927A5 publication Critical patent/JP2012502927A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2011527166A 2008-09-22 2009-09-17 Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体 Pending JP2012502927A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19278708P 2008-09-22 2008-09-22
US61/192,787 2008-09-22
US17243909P 2009-04-24 2009-04-24
US61/172,439 2009-04-24
PCT/CA2009/001321 WO2010031183A1 (en) 2008-09-22 2009-09-17 Indole derivatives as crth2 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2012502927A true JP2012502927A (ja) 2012-02-02
JP2012502927A5 JP2012502927A5 (enExample) 2012-10-25

Family

ID=42039054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527166A Pending JP2012502927A (ja) 2008-09-22 2009-09-17 Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体

Country Status (6)

Country Link
US (1) US8637671B2 (enExample)
EP (1) EP2346865B1 (enExample)
JP (1) JP2012502927A (enExample)
AU (1) AU2009295230A1 (enExample)
CA (1) CA2737483A1 (enExample)
WO (1) WO2010031183A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507998A (ja) * 2014-03-17 2017-03-23 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737460C (en) * 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EP2492267B1 (en) 2009-02-24 2014-11-26 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient
NZ603108A (en) 2010-03-22 2014-05-30 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
KR20130133219A (ko) 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
WO2012087872A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
HUE028972T2 (en) * 2011-04-14 2017-01-30 Actelion Pharmaceuticals Ltd 7- (Heteroarylamino) -6,7,8,9-tetrahydropyrido [1,2-a] indole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
MX2013014900A (es) 2011-06-17 2014-02-17 Merck Sharp & Dohme Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2.
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
EP3258929B1 (en) * 2015-02-16 2022-04-27 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DK3277722T3 (da) 2015-04-02 2021-10-11 Intervet Int Bv Antistoffer mod canin interleukin-4 receptor alpha
WO2017005766A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycic alcohol intermediates of crth2 antagonists
WO2017005759A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make azaindole derivatives
PL3350179T3 (pl) 2015-09-15 2021-08-02 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
CN120514846A (zh) 2019-12-20 2025-08-22 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019675A1 (en) * 2005-08-12 2007-02-22 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
RU2342386C2 (ru) * 2002-10-30 2008-12-27 Мерк Фросст Кэнада Лтд Производные пиридопирролизина и пиридоиндолизина
WO2006125179A1 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
TW200902016A (en) * 2007-05-22 2009-01-16 Taigen Biotechnology Co Ltd Kinesin inhibitors
JP2011500584A (ja) 2007-10-10 2011-01-06 ケミエテック，エルエルシ− Ｃｒｔｈ２受容体拮抗薬としての複素環化合物
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
CA2737460C (en) 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EP2492267B1 (en) * 2009-02-24 2014-11-26 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019675A1 (en) * 2005-08-12 2007-02-22 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507998A (ja) * 2014-03-17 2017-03-23 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用

Also Published As

Publication number Publication date
WO2010031183A1 (en) 2010-03-25
EP2346865A4 (en) 2012-05-23
AU2009295230A1 (en) 2010-03-25
US8637671B2 (en) 2014-01-28
EP2346865B1 (en) 2015-07-15
US20110172263A1 (en) 2011-07-14
EP2346865A1 (en) 2011-07-27
CA2737483A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
JP2012502927A (ja) Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体
RU2451019C2 (ru) Гетероциклические соединения в качестве антагонистов crth2 рецептора
US8546422B2 (en) Azaindole derivatives as CRTH2 receptor antagonists
CA2618550C (en) Indole derivatives as crth2 receptor antagonists
EP1558614B1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
HRP20021039A2 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP2012502926A (ja) Ｃｒｔｈ２受容体アンタゴニストとしてのインドール誘導体
HK1147674B (en) Heterocyclic compounds as crth2 receptor antagonists

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140422